Artiva Biotherapeutics (ARTV) Income towards Parent Company (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Income towards Parent Company data on file, last reported at -$23.5 million in Q1 2026.

• Income towards Parent Company for Q1 2026 came in at -$23.5 million, down 15.81% year-over-year; the trailing twelve-month figure through Mar 2026 was -$87.1 million (down 27.28% YoY), and the FY2025 annual result was -$83.9 million, down 28.27% from the prior year.
• Income towards Parent Company retreated to -$23.5 million in Q1 2026 per ARTV's latest filing, from -$20.8 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at $13.3 million in Q4 2023 and troughed at -$23.5 million in Q1 2026.
• A 4-year average of -$13.0 million and a median of -$16.3 million in 2024 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2024 and 2026: Income towards Parent Company tumbled 246.84% in 2024, then decreased 15.81% in 2026.
• A 4-year view of Income towards Parent Company shows it stood at $13.3 million in 2023, then sank by 221.42% to -$16.1 million in 2024, then declined by 29.09% to -$20.8 million in 2025, then slipped by 13.23% to -$23.5 million in 2026.
• Business Quant data shows ARTV's Income towards Parent Company at -$23.5 million in Q1 2026, -$20.8 million in Q4 2025, and -$21.5 million in Q3 2025.